PriceTargets.com logo

Relmada Therapeutics - RLMD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.25
  • Forecasted Upside: 1,075.01%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.36 As of 12/17/2024 01:00 AM ET
▼ -0.03 (-7.66%)

This chart shows the closing price for RLMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Relmada Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RLMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RLMD

Analyst Price Target is $4.25
▲ +1,075.01% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Relmada Therapeutics in the last 3 months. The average price target is $4.25, with a high forecast of $13.00 and a low forecast of $1.00. The average price target represents a 1,075.01% upside from the last price of $0.36.

This chart shows the closing price for RLMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Relmada Therapeutics. This rating has held steady since August 2024, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2024MizuhoReiterated RatingOutperform ➝ Neutral$23.00 ➝ $1.00
12/4/2024MizuhoDowngradeStrong-Buy ➝ Hold$23.00 ➝ $1.00
12/4/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
12/4/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $1.00
9/17/2024Jefferies Financial GroupUpgradeHold ➝ Buy$3.50 ➝ $13.00
6/5/2024The Goldman Sachs GroupDowngradeNeutral ➝ Sell$3.00 ➝ $2.00
8/10/2023MizuhoLower Target$26.00 ➝ $25.00
1/23/2023Leerink PartnersLower TargetOutperform$42.00 ➝ $10.00
12/8/2022Truist FinancialLower Target$7.00 ➝ $4.00
11/16/2022MizuhoLower Target$34.00
11/16/2022Truist FinancialLower Target$7.00
11/14/2022OppenheimerUpgradeMarket Perform ➝ Outperform
10/20/2022GuggenheimDowngradeNeutral
10/14/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$81.00 ➝ $8.00
10/14/2022GuggenheimDowngradeBuy ➝ Neutral
10/13/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
10/13/2022OppenheimerDowngradeOutperform ➝ Market Perform$64.00 ➝ $7.00
10/13/2022Truist FinancialDowngradeBuy ➝ Hold$90.00 ➝ $10.00
9/23/2022The Goldman Sachs GroupBoost TargetBuy$49.00 ➝ $81.00
9/6/2022GuggenheimBoost TargetBuy$50.00 ➝ $60.00
5/9/2022OppenheimerLower Target$75.00 ➝ $64.00
3/24/2022The Goldman Sachs GroupLower TargetBuy$69.00 ➝ $53.00
12/20/2021Leerink PartnersLower TargetOutperform$50.00 ➝ $42.00
11/17/2021MizuhoInitiated CoverageBuy$50.00
7/27/2021Truist FinancialReiterated RatingBuy$24.55
7/27/2021Truist FinancialBoost TargetPositive ➝ Buy$75.00 ➝ $90.00
5/20/2021The Goldman Sachs GroupInitiated CoverageBuy$78.00
3/17/2021OppenheimerReiterated RatingBuy
10/28/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$69.00 ➝ $40.00
7/13/2020OppenheimerInitiated CoverageOutperform$75.00
5/4/2020SunTrust BanksInitiated CoverageBuy$75.00
4/21/2020The Goldman Sachs GroupInitiated CoverageBuy$63.00
1/27/2020Jefferies Financial GroupInitiated CoverageBuy$75.00
1/10/2020Leerink PartnersReiterated RatingOutperform
(Data available from 12/18/2019 forward)

News Sentiment Rating

-0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Relmada Therapeutics logo
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Read More

Today's Range

Now: $0.36
Low: $0.35
High: $0.39

50 Day Range

MA: $2.70
Low: $0.36
High: $3.64

52 Week Range

Now: $0.36
Low: $0.35
High: $7.22

Volume

1,123,496 shs

Average Volume

337,775 shs

Market Capitalization

$10.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Relmada Therapeutics?

The following Wall Street analysts have issued research reports on Relmada Therapeutics in the last twelve months: Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Mizuho, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RLMD.

What is the current price target for Relmada Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Relmada Therapeutics in the last year. Their average twelve-month price target is $4.25, suggesting a possible upside of 1,075.0%. Jefferies Financial Group Inc. has the highest price target set, predicting RLMD will reach $13.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $1.00 for Relmada Therapeutics in the next year.
View the latest price targets for RLMD.

What is the current consensus analyst rating for Relmada Therapeutics?

Relmada Therapeutics currently has 1 sell rating, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RLMD, but not buy more shares or sell existing shares.
View the latest ratings for RLMD.

What other companies compete with Relmada Therapeutics?

Other companies that are similar to Relmada Therapeutics include Exicure, Synergy CHC Corp. (Uplisting), Atlantic Coastal Acquisition Corp. II, Cardio Diagnostics and Aileron Therapeutics. Learn More about companies similar to Relmada Therapeutics.

How do I contact Relmada Therapeutics' investor relations team?

Relmada Therapeutics' physical mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The company's listed phone number is (786) 629-1376 and its investor relations email address is [email protected]. The official website for Relmada Therapeutics is www.relmada.com. Learn More about contacing Relmada Therapeutics investor relations.